Physician profile
Lu Zhang
NPI 1063933612
$998.84
in general payments reported to CMS, 2019-2025
16 companies · $46.30 in 2025
The $46.30 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2023: $245 · 2024: $311 · 2025: $46.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.78 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $163.21 | 2023-2024 | Airsupra, Farxiga |
| Amgen INC. | $116.26 | 2021-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $80.96 | 2021-2023 | Myrbetriq, Veozah |
| Novo Nordisk INC | $80.84 | 2021-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $80.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $75.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $48.26 | 2021 | |
| Exact Sciences Corporation | $27.14 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $24.90 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $23.41 | 2023 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $21.56 | 2024 | |
| Merck Sharp & Dohme LLC | $19.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.60 | 2024 | Ofev |
| Lundbeck LLC | $16.21 | 2024 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lu Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.